Publication:
Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

dc.contributor.authorRedondo, Andres
dc.contributor.authorOaknin, Ana
dc.contributor.authorRubio, Maria Jesus
dc.contributor.authorBarretina-Ginesta, Maria-Pilar
dc.contributor.authorde Juan, Ana
dc.contributor.authorManso, Luis
dc.contributor.authorRomero, Ignacio
dc.contributor.authorMartin-Lorente, Cristina
dc.contributor.authorPoveda, Andres
dc.contributor.authorGonzalez-Martin, Antonio
dc.date.accessioned2023-02-09T11:38:57Z
dc.date.available2023-02-09T11:38:57Z
dc.date.issued2021-05-26
dc.description.abstractTo determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with a group of Spanish gynecologists and medical oncologists specially dedicated to gynecological tumors. The questionnaire was developed by the byline authors. All questions but one were answered using a 9-item Likert-like scale with three types of answers: frequency, relevance and agreement. We performed two rounds between December 2018 and July 2019. A consensus was considered reached when at least 75% of the answers were located within three consecutive points of the Likert scale. In the first round, 32 oncologists and gynecologists were invited to participate, and 31 (96.9%) completed the online questionnaire. In the second round, 27 (87.1%) completed the online questionnaire. The results for the questions on first-line management of advanced disease, treatment of patients with recurrent disease for whom platinum might be the best option, and treatment of patients with recurrent disease for whom platinum might not be the best option are presented. This survey shows a snapshot of current recommendations by this selected group of physicians. Although the majority of the agreements and recommendations are aligned with the recently published ESMO-ESGO consensus, there are some discrepancies that can be explained by differences in the interpretation of certain clinical trials, reimbursement or accessibility issues.
dc.identifier.doi10.1186/s13048-021-00816-x
dc.identifier.essn1757-2215
dc.identifier.pmcPMC8157411
dc.identifier.pmid34039386
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157411/pdf
dc.identifier.unpaywallURLhttps://ovarianresearch.biomedcentral.com/counter/pdf/10.1186/s13048-021-00816-x
dc.identifier.urihttp://hdl.handle.net/10668/17837
dc.issue.number1
dc.journal.titleJournal of ovarian research
dc.journal.titleabbreviationJ Ovarian Res
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Reina Sofía
dc.page.number72
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAdvanced disease
dc.subjectConsensus
dc.subjectManagement
dc.subjectOvarian cancer
dc.subjectRecurrent disease
dc.subject.meshConsensus
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshOvarian Neoplasms
dc.subject.meshSpain
dc.subject.meshSurveys and Questionnaires
dc.titleManagement of advanced ovarian cancer in Spain: an expert Delphi consensus.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8157411.pdf
Size:
4.73 MB
Format:
Adobe Portable Document Format